MedTrace Logo

Tau Imaging in Young Onset Dementia

NCT02289118 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2020-03-25

No results posted yet for this study

Summary

The central goal of this study is to determine and compare the similarities and differences in regional brain uptake of \[18F\]T807 in patients with typical Alzheimer's Disease (AD), Posterior Cortical Atrophy (PCA), and Logopenic Variant of Primary Progressive Aphasia (lvPPA). The investigators will correlate patterns of \[18F\]T807 binding with magnetic resonance imaging (MRI)-based regional volumetric and cortical thickness measures. If cerebral spinal fluid (CSF) samples are not available, patients may be asked to get an optional lumbar puncture (LP) for additional comparisons. The investigators will recruit 20 participants, 45-70 years old, with clinical evidence of young onset focal dementia.

Conditions

  • Alzheimer's Disease, Early Onset
  • Logopenic Progressive Aphasia
  • Posterior Cortical Atrophy (PCA)

Interventions

DRUG

[18F]-T807 imaging tracer

Tau Imaging tracer

Sponsors & Collaborators

Principal Investigators

  • David Wolk, MD · University of Pennsylvania

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-12-31
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289118 on ClinicalTrials.gov